You are here:
Name SMC ID No Manufacturer Status Sub. Type
 
abatacept (Orencia) 618/10 Bristol-Myers Squibb Pharmaceuticals Ltd Not Recommended Non submission
abatacept (Orencia) 618/10 Bristol-Myers Squibb Pharmaceuticals Ltd Superseded Abbreviated Submission
abatacept (Orencia) 719/11 Bristol-Myers Squibb Pharmaceuticals Ltd Not Recommended Full submission
abatacept (Orencia) 719/11 Bristol-Myers Squibb Pharmaceuticals Ltd Superseded Resubmission
abatacept (Orencia) 1230/17 Bristol-Myers Squibb Pharmaceuticals Ltd Not Recommended Non submission
abatacept (Orencia) 1287/17 Bristol-Myers Squibb Pharmaceuticals Ltd Not Recommended Non submission
abatacept 125mg/mL solution for subcutaneous injection in a pre-filled syringe (Orencia®) 888/13 Bristol-Myers Squibb Pharmaceuticals Ltd Superseded Abbreviated Submission
abatacept 250mg powder for concentrate for solution (Orencia) 400/07 Bristol-Myers Squibb Pharmaceuticals Ltd Superseded Full submission
adalimumab (Humira) 533/09 Abbott Laboratories Superseded Abbreviated Submission
adalimumab (Humira) 738/11 Abbott Laboratories Superseded Abbreviated Submission
adalimumab (Humira) 858/13 AbbVie Ltd Superseded Full submission
adalimumab (Humira) 1173/16 AbbVie Ltd Not Recommended Non submission
adalimumab (Humira) 1050/15 AbbVie Ltd Restricted Abbreviated Submission
adalimumab (Humira) 881/13 AbbVie Ltd Superseded Abbreviated Submission
adalimumab (Humira) 81/03 Abbott Laboratories Superseded Full submission
adalimumab (Humira) 1068/15 AbbVie Ltd Superseded Abbreviated Submission
adalimumab (Humira) 1209/16 AbbVie Ltd Superseded Non submission
adalimumab (Humira) 1305/18 AbbVie Ltd Not Recommended Non submission
adalimumab 40mg pre-filled syringe (Humira) 300/06 Abbott Laboratories Superseded Full submission
amifampridine (Firdapse) 660/10 BioMarin Not Recommended Non submission
amifampridine (Firdapse) 660/10 BioMarin Not Recommended Full submission
anakinra (Kineret) 1116/15 Swedish Orphan Not Recommended Non submission
Anakinra (Kineret®) 05/02 Amgen Ltd Not Recommended Resubmission
Anakinra (Kineret®) 05/02 Amgen Ltd Not Recommended Full submission
apremilast (Otezla) plaque psoriasis 1052/15 Celgene Ltd Accepted Full submission
apremilast (Otezla) psoriatic arthritis 1053/15 Celgene Ltd Restricted Full submission
ataluren (Translarna) 1131/16 PTC Therapeutics Not Recommended Full submission
baricitinib (Olumiant) 1265/17 Eli Lilly and Company Ltd Restricted Full submission
belimumab (Benlysta) 775/12 GlaxoSmithKline UK Ltd Restricted Resubmission
canakinumab (Ilaris) 1268/17 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
cannabinoid (Sativex) 703/11 Bayer plc/Bayer Schering Pharma Not Recommended Non submission
capsaicin (Qutenza) 673/11 Astellas Pharma Ltd Restricted Resubmission
capsaicin (Qutenza) 1140/16 Astellas Pharma Ltd Not Recommended Non submission
capsaicin cutaneous patch (Qutenza) 673/11 Astellas Pharma Ltd Restricted Full submission
celecoxib (Celebrex) 410/07 Pfizer Ltd Not Recommended Non submission
certolizumab pegol (Cimzia) 590/09 UCB Pharma Ltd Not Recommended Full submission
certolizumab pegol (Cimzia) 590/09 UCB Pharma Ltd Superseded Resubmission
certolizumab pegol (Cimzia) 1155/16 UCB Pharma Ltd Not Recommended Non submission
certolizumab pegol (Cimzia) 960/14 UCB Pharma Ltd Superseded Full submission
certolizumab pegol (Cimzia) 973/14 UCB Pharma Ltd Superseded Full submission
collagenase (Xiapex) 715/11 Pfizer Ltd Superseded Resubmission
collagenase clostridium histolyticum (Xiapex) 715/11 Pfizer Ltd Not Recommended Full submission
collagenase clostridum histolyticum (Xiapex) 1059/15 Swedish Orphan Not Recommended Non submission
dibotermin alfa (InductOs) 365/07 Medtronic Restricted Full submission
diclofenac (Mobigel Spray) 667/10 Goldshield Pharmaceuticals Limited Not Recommended Non submission
Diclofenac (Voltarol Gel Patch®) 199/05 Novartis Pharmaceuticals UK Ltd Not Recommended Full submission
diclofenac 75mg/2ml solution for injection (Dyloject) 446/08 Javelin Pharmaceuticals UK Ltd Restricted Full submission
etanercept (Enbrel) 782/12 Pfizer Ltd Superseded Abbreviated Submission
etanercept (Enbrel) 212/05 Wyeth Pharmaceuticals Superseded Full submission
etanercept (Enbrel) 781/12 Pfizer Ltd Superseded Abbreviated Submission
Etanercept (Enbrel®) 107/04 Wyeth Pharmaceuticals Superseded Full submission
etanercept 50mg subcutaneous injection (Enbrel) 304/06 Wyeth Pharmaceuticals Accepted Abbreviated Submission
etanercept 50mg subcutaneous injection (Enbrel) 303/06 Wyeth Pharmaceuticals Superseded Abbreviated Submission
etanercept 50mg subcutaneous injection (Enbrel) 305/06 Wyeth Pharmaceuticals Superseded Abbreviated Submission
etoricoxib (Arcoxia) 576/09 MSD Not Recommended Non submission
etoricoxib (Arcoxia) 847/12 MSD Not Recommended Non submission
etoricoxib (Arcoxia) 31/03 MSD Accepted Full submission
etoricoxib 60mg, 90mg and 120mg tablets (Arcoxia) 313/06 MSD Accepted Abbreviated Submission
fampridine (Fampyra) 789/12 Biogen Idec Ltd Not Recommended Non submission
fampridine (Fampyra)  789/12 Biogen Idec Ltd Not Recommended Full submission
febuxostat (Adenuric) 637/10 Menarini Pharmaceuticals UK Restricted Full submission
febuxostat (Adenuric) 1153/16 Menarini Pharmaceuticals UK Restricted Full submission
glucosamine (Alateris) 471/08 William Ransom and Son plc Not Recommended Full submission
glucosamine sulphate (Dolenio®) 729/11 Not Recommended Non submission
glucosamine sulphate (Glusartel) 647/10 HFA Healthcare Ltd Not Recommended Resubmission
glucosamine sulphate sodium chloride (Glusartel) 647/10 HFA Healthcare Ltd Not Recommended Full submission
golimumab (Simponi) 674/11 MSD Accepted Resubmission
golimumab (Simponi) 733/11 MSD Superseded Full submission
golimumab (Simponi) 1124/16 MSD Accepted Full submission
golimumab (Simponi) 946/13 MSD Not Recommended Non submission
golimumab (Simponi) (AS) 721/11 MSD Superseded Full submission
golimumab (Simponi®) 1199/16 MSD Not Recommended Non submission
Ibuprofen intravenous injection 5mg/ml (Pedea®) 233/06 Orphan Europe (UK) Ltd Accepted Abbreviated Submission
infliximab (Inflectra) 1007/14 Hospira UK Limited Superseded Full submission
infliximab (Remicade) 739/11 MSD Not Recommended Non submission
infliximab (Remicade) 854/13 MSD Superseded Full submission
infliximab (Remicade) 101/04 Schering-Plough Ltd Superseded Full submission
infliximab (Remsima) 1006/14 Celltrion Healthcare Hungary Kft Superseded Full submission
ketoprofen / omeprazole (Axorid) 606/10 Meda Pharmaceuticals Ltd Accepted Resubmission
ketoprofen / omeprazole (Axorid) 606/10 Meda Pharmaceuticals Ltd Full submission
Lumiracoxib 100mg tablets (Prexige®) 245/06 Novartis Pharmaceuticals UK Ltd Marketing Authorisation Withdrawn Full submission
mercaptamine (Procysbi) 1272/17 Horizon Pharma Not Recommended Full submission
methotrexate (Metoject 50mg/ml) 573/09 Medac UK Accepted Abbreviated Submission
methotrexate 50mg/ml solution for injection (Metoject®) 724/11 Medac UK Accepted Abbreviated Submission
methotrexate injection 10mg/ml, (Metoject) 332/06 Medac UK Accepted Abbreviated Submission
naproxen (Stirlescent) 1154/16 Stirling Anglian Pharmaceuticals Restricted Abbreviated Submission
naproxen + esomeprazole (Vimovo) 734/11 AstraZeneca UK Ltd Not Recommended Full submission
Parecoxib (Dynastat®) 27/02 Pharmacia Not Recommended Full submission
rituximab 100mg/10ml, 500mg/50ml ml solution for intravenous infusion (MabThera) 323/06 Roche Superseded Full submission
secukinumab (Cosentyx) 1159/16 Novartis Pharmaceuticals UK Ltd Accepted Full submission
secukinumab (Cosentyx) 1054/15 Novartis Pharmaceuticals UK Ltd Restricted Full submission
secukinumab (Cosentyx) 1167/16 Novartis Pharmaceuticals UK Ltd Superseded Full submission
tocilizumab (RoActemra) 593/09 Roche Superseded Full submission
tocilizumab (RoActemra) 754/12 Roche Accepted Full submission
tocilizumab (RoActemra) 774/12 Roche Not Recommended Full submission
tocilizumab (RoActemra) 774/12 Roche Superseded Resubmission
tocilizumab (RoActemra®) 1201/16 Roche Not Recommended Non submission
tocilizumab (RoActemra®) 1020/14 Roche Not Recommended Non submission
tocilizumab (RoActemra®) 982/14 Roche Restricted Full submission
tocilizumab (RoActerma) 930/13 Roche Superseded Abbreviated Submission
triamcinolone hexacetonide 1103/15 Intrapharm Laboratories Ltd Accepted Abbreviated Submission
Valdecoxib (Bextra®) 89/04 Pfizer Ltd Advice has been withdrawn from the Website Full submission

Back